Completion of phase II clinical trial on COVID-19 patients
Filed with ASX · · 3 pages · English
Earlier from Argent Biopharma
- September Quarterly Activity and Cashflow Report
- Mgc pharma delivers record consecutive weekly sales growth
- ArtemiC histology on rats confirm no pathological impact
- First high THC products shipped direct to Brazil patients
- MGC pharma launches CannEpil app
Later from Argent Biopharma
- Further successful results from glioblastoma research
- MGC pharma completes acquisition of telehealth platform MCC
- Prospectus
- ArtemiC Phase II Clinical Trial Results
- December Quarterly Activity and Cashflow Report
Follow Argent Biopharma into a list and get an email when it puts out news.
Follow Argent Biopharma